Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Nivolumab en ipilimumab voor gevorderd niercelcarcinoom
apr 2018 | Uro-oncologie